DS-6157a, A GPR20 Targeting ADC for the Treatment of Gastrointestinal Stromal Tumor (GIST)

Time: 4:00 pm


  • GPR20 is an orphan GPCR, selectively and abundantly expressed in GIST
  • DS-6157a is a DNA topoisomerase I inhibitor Exatecan-derivative based ADC, entering phase I trial in 2020
  • In preclinical studies, DS-6157a showed antitumor activity and preferable safety profiles